A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
Inclusion Criteria:
Exclusion Criteria:
Northridge, California 91328, United States
Jacksonville, Florida 32256, United States
Detroit, Michigan 48201, United States
Provincia de Buenos Aires, B1884BBF, Argentina
Innsbruck, 6020, Austria
Montreal, Quebec H3T 1E2, Canada
Recoleta, 8420383, Chile
Marseille, 13915, France
Regensburg, 93053, Germany
Thermi Thessalonikis, 570 01, Greece
Aviano, Friuli Venezia Giulia 33081, Italy
Udine, Friuli Venezia Giulia 33100, Italy
Pisa, Tuscany 56124, Italy
Verona, Veneto 37134, Italy
Ehime, 791-0280, Japan
Osaka, 591-8555, Japan
Yamaguchi, 755-0241, Japan
Auckland, 1023, New Zealand
Lodz, 93-513, Poland
Warsaw, 02-781, Poland
Gyeonggi-do, 463-707, South Korea
Las Palmas de Gran Canaria, LAS Palmas 35016, Spain
A Coruña, 15006, Spain